^
    Back
    Association details:
    Biomarker:PTEN expression
    Cancer:Colorectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Biomarks of Resistance to Cetuximab in Colorectal Cancer

    Excerpt:
    ...KRAS gene sequence - KRAS gene sequence; NRAS gene sequence - NRAS gene sequence; BRAF gene sequence - BRAF gene sequence; PIK3CA gene sequence - PIK3CA gene sequence; EGFR gene sequence - EGFR gene sequence; EGFR gene copy numbers - EGFR gene copy numbers; EGFR expression - EGFR expression; Her2 expression - Her2 expression; c-Met expression - c-Met expression; PTEN expression - PTEN expression; Progression-free survival - Progression-free survival; Overall survival - Overall survival; Rash - Rash; Diarrhea - Diarrhea; vomiting - vomiting; White blood cell count - White blood cell count; Platelet count - Platelet count; Hemoglobin - Hemoglobin; Red blood cell count - Red blood cell count...
    Trial ID:
    ChiCTR-ROB-15006385
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer

    Excerpt:
    We retrospectively collected tumors from 173 patients with mCRC. All but one patient received a cetuximab-based regimen as second-line or greater therapy...PTEN null expression was found in 19.9% of the patients and was associated with shorter OS (P = .013). In multivariate analysis, BRAF mutation and PTEN expression status were associated with OS.
    DOI:
    10.1200/JCO.2008.21.6796